Pharvaris Unveils New Clinical Data on Oral Deucrictibant for Hereditary Angioedema at ACAAI 2025

Reuters

10/23

Pharvaris Unveils New Clinical Data on Oral Deucrictibant for Hereditary Angioedema at ACAAI 2025

Pharvaris NV has announced the acceptance of two oral presentations and six poster presentations at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) 2025 Annual Scientific Meeting, scheduled for November 6-10, 2025, in Orlando, Florida. The presentations will include new clinical data on the company's oral bradykinin B2 receptor antagonist, deucrictibant, for the prophylaxis and treatment of hereditary angioedema $(HAE)$. Topics include the clinical validation of a kinin biomarker assay, long-term safety and efficacy of oral deucrictibant, and comparative analyses with standard of care. The results are scheduled to be presented during the conference, and the associated posters and slides will be made available on the Pharvaris website at the time of the presentations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9549792-en) on October 23, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2577308795"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577308795\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577308795?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-23 18:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577308795","market":"nz","top_or_hot":-1,"title":"Pharvaris Unveils New Clinical Data on Oral Deucrictibant for Hereditary Angioedema at ACAAI 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pharvaris Unveils New Clinical Data on Oral Deucrictibant for Hereditary Angioedema at ACAAI 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pharvaris NV has announced the acceptance of two oral presentations and six poster presentations at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) 2025 Annual Scientific Meeting, scheduled for November 6-10, 2025, in Orlando, Florida. The presentations will include new clinical data on the company's oral bradykinin B2 receptor antagonist, deucrictibant, for the prophylaxis and treatment of hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a>. Topics include the clinical validation of a kinin biomarker assay, long-term safety and efficacy of oral deucrictibant, and comparative analyses with standard of care. The results are scheduled to be presented during the conference, and the associated posters and slides will be made available on the Pharvaris website at the time of the presentations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9549792-en) on October 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharvaris Unveils New Clinical Data on Oral Deucrictibant for Hereditary Angioedema at ACAAI 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharvaris Unveils New Clinical Data on Oral Deucrictibant for Hereditary Angioedema at ACAAI 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-23 18:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pharvaris Unveils New Clinical Data on Oral Deucrictibant for Hereditary Angioedema at ACAAI 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pharvaris NV has announced the acceptance of two oral presentations and six poster presentations at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) 2025 Annual Scientific Meeting, scheduled for November 6-10, 2025, in Orlando, Florida. The presentations will include new clinical data on the company's oral bradykinin B2 receptor antagonist, deucrictibant, for the prophylaxis and treatment of hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a>. Topics include the clinical validation of a kinin biomarker assay, long-term safety and efficacy of oral deucrictibant, and comparative analyses with standard of care. The results are scheduled to be presented during the conference, and the associated posters and slides will be made available on the Pharvaris website at the time of the presentations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9549792-en) on October 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nNDL5lKgy3:1","article_id":"2577308795","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577308795","pubTimestamp":1761216617,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pharvaris NV has announced the acceptance of two oral presentations and six poster presentations at the upcoming American College of Allergy, Asthma, and Immunology  2025 Annual Scientific Meeting, scheduled for November 6-10, 2025, in Orlando, Florida. The presentations will include new clinical data on the company's oral bradykinin B2 receptor antagonist, deucrictibant, for the prophylaxis and treatment of hereditary angioedema . Topics include the clinical validation of a kinin biomarker assay, long-term safety and efficacy of oral deucrictibant, and comparative analyses with standard of care. The results are scheduled to be presented during the conference, and the associated posters and slides will be made available on the Pharvaris website at the time of the presentations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informatio","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4007":"制药","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","PHVS":"Pharvaris N.V.","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"Pharvaris在ACAAI 2025上公布口服Deucrictibant治疗遗传性血管性水肿的新临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"PHVS":0.9},"content_text":"Pharvaris Unveils New Clinical Data on Oral Deucrictibant for Hereditary Angioedema at ACAAI 2025\n    \n\n        Pharvaris NV has announced the acceptance of two oral presentations and six poster presentations at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) 2025 Annual Scientific Meeting, scheduled for November 6-10, 2025, in Orlando, Florida. The presentations will include new clinical data on the company's oral bradykinin B2 receptor antagonist, deucrictibant, for the prophylaxis and treatment of hereditary angioedema $(HAE)$. Topics include the clinical validation of a kinin biomarker assay, long-term safety and efficacy of oral deucrictibant, and comparative analyses with standard of care. The results are scheduled to be presented during the conference, and the associated posters and slides will be made available on the Pharvaris website at the time of the presentations.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9549792-en) on October 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}